MedTrace Logo

Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study

NCT02450513 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-07-10

No results posted yet for this study

Summary

Observational pharmacokinetics study of adalimumab in patients with active refractory Crohn's disease who are naïve to TNF antagonist therapy.

Conditions

Interventions

DRUG

Adalimumab

160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-05-25
Completion
2016-05-25

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02450513 on ClinicalTrials.gov